Wysa raises Rs 160 crore in funding round
Advertisement
New Delhi: IT platform for mental health therapy Wysa has raised USD 20 million (about Rs 160 crore) in a funding round led by HealthQuad, the company said on Thursday. Wysa plans to use the capital to expand into the US, the UK, India and other global markets across enterprises, payors, providers as well as improve wider usability through multi-lingual support and easier access via WhatsApp.
The UK's development finance institution British International Investment (BII) also participated in the funding round.
Existing investors of the start-up include W Health Ventures, Kae Capital, Google Assistant Investments, and pi Ventures amongst others.
The firm provides an AI-enabled conversation platform to support users and in the second level provide access to high-level techniques with human support.
Wysa in the third level provides solutions for clinical trials.
"The funding that we are raising is to scale up the first and second layer and build out the third level," Wysa co-founder Ramakant Vempati said.
The start-up at present has 4.5 million revenue-generating users across 65 countries.
The company Wysa has achieved FDA Breakthrough device designation for its AI-based digital mental health conversational agent for adults with a diagnosis of chronic musculoskeletal pain and associated depression and anxiety.
Wysa clients include Accenture, Colgate-Palmolive, Aetna International, Swiss Re, the National Health Service (NHS) in the UK, and the Ministry of Health in Singapore. PTI PRS MR
Read also: MedTech startup EzeRx raises undisclosed amount as seed funding from Mankind Pharma promoters
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.